{Reference Type}: Journal Article
{Title}: Prostanoid signaling in retinal vascular diseases.
{Author}: Stark AK;Penn JS;
{Journal}: Prostaglandins Other Lipid Mediat
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 30
{Factor}: 3.813
{DOI}: 10.1016/j.prostaglandins.2024.106864
{Abstract}: The vasculature of the retina is exposed to systemic and local factors that have the capacity to induce several retinal vascular diseases, each of which may lead to vision loss. Prostaglandin signaling has arisen as a potential therapeutic target for several of these diseases due to the diverse manners in which these lipid mediators may affect retinal blood vessel function. Previous reports and clinical practices have investigated cyclooxygenase (COX) inhibition by nonsteroidal anti-inflammatory drugs (NSAIDs) to address retinal diseases with varying degrees of success; however, targeting individual prostanoids or their distinct receptors affords more signaling specificity and poses strong potential for therapeutic development. This review offers a comprehensive view of prostanoid signaling involved in five key retinal vascular diseases: retinopathy of prematurity, diabetic retinopathy, age-related macular degeneration, retinal occlusive diseases, and uveitis. Mechanistic and clinical studies of these lipid mediators provide an outlook for therapeutic development with the potential to reduce vision loss in each of these conditions.